FGFR3 and neoplasm: We observed that 0.06% of aNSCLC samples in the GH database had FGFR3-TACC3 fusion with a concurrent EGFR mutation, similar to the results reported by Ou et al. (0.03%; 5 of 17,319 aNSCLC cases) using either tumor tissue or plasma as source material [12], but somewhat greater than those reported by Quin et al. (0.007%) using tumor tissue only [19].